Free Trial

Cantor Fitzgerald Analysts Lift Earnings Estimates for TNGX

Tango Therapeutics logo with Medical background

Key Points

  • Cantor Fitzgerald has upgraded their FY2025 earnings per share estimate for Tango Therapeutics from ($1.35) to ($0.97), reflecting improved expectations for the company's financial performance.
  • Guggenheim and HC Wainwright have both issued "buy" ratings for Tango Therapeutics, with price targets of $10.00 and $13.00 respectively, suggesting strong market confidence in the company's future growth.
  • As of the latest quarter, Tango Therapeutics reported earnings of ($0.35) per share, meeting analysts' expectations but falling short on revenue with $3.18 million compared to the forecasted $6.41 million.
  • Need Better Tools to Track Tango Therapeutics? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Tango Therapeutics in a note issued to investors on Wednesday, August 6th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings of ($0.97) per share for the year, up from their prior forecast of ($1.35). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. Cantor Fitzgerald also issued estimates for Tango Therapeutics' FY2026 earnings at ($1.83) EPS.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The company had revenue of $3.18 million during the quarter, compared to analyst estimates of $6.41 million. Tango Therapeutics had a negative net margin of 599.11% and a negative return on equity of 79.72%.

A number of other research analysts also recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Tango Therapeutics in a research report on Monday, April 14th. Guggenheim increased their target price on Tango Therapeutics from $8.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday.

Check Out Our Latest Report on Tango Therapeutics

Tango Therapeutics Stock Performance

TNGX remained flat at $6.61 during trading on Friday. 999,390 shares of the company's stock were exchanged, compared to its average volume of 1,985,156. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $12.02. The business's 50-day simple moving average is $5.56 and its two-hundred day simple moving average is $3.18. The stock has a market capitalization of $735.43 million, a P/E ratio of -4.97 and a beta of 1.64.

Hedge Funds Weigh In On Tango Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CWM LLC lifted its holdings in shares of Tango Therapeutics by 182.2% during the second quarter. CWM LLC now owns 4,905 shares of the company's stock worth $25,000 after purchasing an additional 3,167 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Tango Therapeutics during the fourth quarter worth about $33,000. Stonebrook Private Inc. acquired a new stake in shares of Tango Therapeutics during the fourth quarter worth about $34,000. Ameriprise Financial Inc. acquired a new stake in shares of Tango Therapeutics during the fourth quarter worth about $35,000. Finally, Savant Capital LLC acquired a new stake in shares of Tango Therapeutics during the second quarter worth about $61,000. Hedge funds and other institutional investors own 78.99% of the company's stock.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Further Reading

Earnings History and Estimates for Tango Therapeutics (NASDAQ:TNGX)

Should You Invest $1,000 in Tango Therapeutics Right Now?

Before you consider Tango Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.

While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines